Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02706873 · ClinicalTrials.gov registry record · Phase 3
A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate
A Phase 3 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,002
- Enrollment target
NCT02706873 is a Phase 3 study that has completed, run by AbbVie. The registered enrollment target is 1,002 participants.
The verdict
NCT02706873, a Phase 3 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,002 participants
- Enrollment target
Study Summary
The objectives of Period 1 were the following: * To compare the safety and efficacy of upadacitinib 7.5 mg once daily (QD) monotherapy (for participants in Japan only), 15 mg QD monotherapy, and 30 mg QD monotherapy versus weekly methotrexate monotherapy for the treatment of signs and symptoms of RA in methotrexate-naïve adults with moderately to severely active RA; * To compare the efficacy of upadacitinib 15 mg QD monotherapy and upadacitinib 30 mg QD monotherapy versus weekly methotrexate monotherapy for prevention of structural progression in methotrexate-naïve adults with moderately to severely active RA. The objective of Period 2 is to evaluate the long-term safety, tolerability, and efficacy of upadacitinib 7.5 mg QD (for participants in Japan only), 15 mg QD, and 30 mg QD in adults with RA who have completed Period 1.
Interventions
- DRUG Upadacitinib
- DRUG Methotrexate
- DRUG Placebo to Upadacitinib
- DRUG Placebo to Methotrexate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,002 participants |
| Start Date | 2016-02-23 |
| Est. Completion | 2022-11-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02706873
The ClinicalTrials.gov registry entry for NCT02706873 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,002 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Upadacitinib is the first listed.
NCT02706873 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02706873 about?
NCT02706873 is a clinical study titled "A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate". The objectives of Period 1 were the following: * To compare the safety and efficacy of upadacitinib 7.5 mg once daily (QD) monotherapy (for participants in Japan only), 15 mg QD monotherapy, and 30 mg QD monotherapy versus weekly methotrexate monotherapy for the treatment of signs and symptoms of R...
What is the current status of trial NCT02706873?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,002 participants. The study started on 2016-02-23. Estimated completion is 2022-11-10.
What interventions are being tested in trial NCT02706873?
The interventions under investigation include: Upadacitinib (DRUG), Methotrexate (DRUG), Placebo to Upadacitinib (DRUG), Placebo to Methotrexate (DRUG).
Who is sponsoring clinical trial NCT02706873?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.